Kyowa Hakko’s Immuse postbiotic ingredient makes debut in Mexico with launch of an immune health supplement by Quifaest

Immo Forte product from Quifaest. Image courtesy of Kyowa Hakko.

Kyowa Hakko USA (New York) has announced that its Immuse postbiotic ingredient is now available in Mexico through the launch of Immo Forte from the pharmaceutical manufacturer Quifaest. Previously, Immuse was only available in the U.S., Canada, and Europe.

“Consumers around the globe are looking for new opportunities to elevate their immune health to ensure that they can power through their days feeling their best,” said Karen Todd, MBA, RD, vice president of Global Brand Marketing, Kyowa Hakko USA, Inc., in a press release. “We’re so excited to have partnered with the Quifaest team to give consumers throughout Mexico a novel option with our first launch in this market.”

According to Kyowa Hakko, Immuse has been the subject of over 30 published clinical studies, including 15 human trials demonstrating its benefits as an immune activator. This research posits that the ingredient supports immune health through a novel mechanism of action, namely the activation of plasmacytoid dendritic cells (pDCs). Kyowa Hakko explains in a press release that pDCs are a rare type of immune cell, functioning as a “key leader” of the immune system, activating pivotal cells such as NK, Killer-T, Helper-T, and B cells.